Skip to Main Content

NEWS & RESOURCES

Bioscience

Positive Session for Bioscience Sector

The 2026 General Assembly session was one of the least contentious in recent memory for the biopharma sector. Bills calling for innovation-sapping price controls and unworkable programs…

Boehringer Partners on Connecticut Science Center STEM Lab

The Connecticut Science Center is home to exhibits, programs, and…

Costly Public Option Precursor Advances

The Connecticut General Assembly is exploring ways to address rising…

Content Type:

Bioscience

Lamont Budget Adjustments Target Affordability, Workforce

Gov. Ned Lamont’s proposed fiscal 2027 budget adjustments include several important...

Bioscience

Lamont Proposes R&D Tax Credits for Small Business

Allowing small businesses to access research and development tax...

Bioscience

Tariffs, TrumpRx, and the Shift to DTC Prescription Drug Sales

The following article was first posted in the Insights section of...

Bioscience

Jackson Lab Acquires NY Stem Cell Foundation

The Jackson Laboratory has completed its acquisition of the...

Bioscience

State Makes $50M New Haven Innovation Investment

The Lamont administration announced a $50.5 million investment in...

Bioscience

Time to Undo the Pill Penalty

The following article first appeared in the Connecticut Mirror’s...

Bioscience

Arvinas board chair John Houston

John Houston Stepping Down as Arvinas CEO

New Haven-based biotech company Arvinas has begun the search...

Bioscience

CBIA BizCast: Reflecting on a Bioscience Career

He’s not calling it retirement. But after a successful...

Bioscience

Legislative Session: Near Misses, Notable Successes for Bioscience

From the perspective of the biopharma sector, the 2025...

Stay Connected with CBIA News Digests

The latest news and information delivered directly to your inbox.